Resources

In this blog, Elisa Petris, Partner at Syncona Investment Management Limited, and Emma Johnson, Senior Investment Manager – Life Sciences at the British Business Bank, write in their capacity as Co-founders of Invest in Equity. They share why they launched the initiative, the urgency of improving gender diversity in life science investment, and how a more inclusive ecosystem can drive stronger returns and better outcomes for patients.

In the third part of our series on Industrial Strategy, Lewis Miles and Maddie Cass provide a deep dive into the Digital and Technologies Sector Plan, analysing how these policies aim to foster growth in the UK's life sciences and engineering biology sectors. We also look forward to strengthening relations and gaining key insight from our US sister organisation with BIO's upcoming UK visit.

In my final summer update as BIA CEO, I reflect on 12 amazing years and look ahead to my new role as Executive Chair of the Office for Life Sciences. This week we’ve also published our latest finance report, and we’re hiring - so if you’re looking for your next challenge, now’s the time to join Team BIA.

From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.

We are heading to Boston this June for the BIO International Convention 2025 – one of the world’s largest and most influential gatherings in the life sciences calendar. 

In this guest blog, Christine Hockley, Managing Director at British Patient Capital, outlines the substantial long-term investment needed to scale innovations.

BIA, MedCity, and London & Partners announce the launch of London Life Sciences Week (LLSW), celebrating the UK’s thriving life sciences ecosystem and bringing together international investors, industry leaders, and cutting-edge innovators.

The UK biotech sector demonstrated encouraging resilience in the third quarter of 2024 raising a total of £808 million in venture capital and public financing. Read our latest report to find out more.

The UK biotech sector secured an impressive £808 million in Q3 2024, defying tough global market conditions and demonstrating sustained investor confidence. Read our latest report to find out more.

CGT Catapult has revealed new data highlighting the UK’s potential to become a global leader in the sector. Its 2024 annual review demonstrates how, with coherent and concerted action, the UK can take the lead in harnessing the potential of these therapies to deliver life-changing benefits to patients and economic growth to the nation.